TO · HLS.TO
HLS Therapeutics Inc.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Etobicoke, ON M9W 6L2
- Website
- hlstherapeutics.com
Price · as of 2024-12-31
$4.64
Market cap 141.27M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $66.50 | +1,333.19% |
| Intrinsic Value(DCF) | $2.71 | -41.59% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $1.40 | -69.83% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $0.00 | $0.00 | |||
| 2011 | $0.00 | $0.00 | |||
| 2012 | $0.00 | $63.00 | |||
| 2013 | $0.00 | $0.00 | |||
| 2014 | $4.70 | $1.30 | |||
| 2015 | $1.40 | $8.40 | |||
| 2016 | $1.20 | $0.00 | |||
| 2017 | $10.78 | $18,045.85 | $610.30 | $8.30 | $0.00 |
| 2018 | $14.86 | $37.79 | $433.23 | $1.00 | $11.90 |
| 2019 | $20.12 | $43.72 | $6.79 | $0.70 | $3.00 |
| 2020 | $19.16 | $53.00 | $5.08 | $0.90 | $0.00 |
| 2021 | $14.82 | $32.14 | $4.83 | $0.80 | $0.00 |
| 2022 | $8.59 | $32.34 | $3.39 | $0.00 | $0.00 |
| 2023 | $4.21 | $35.02 | $2.63 | $0.00 | $0.00 |
| 2024 | $4.04 | $47.62 | $1.81 | $0.00 | $1.40 |
AI valuation
Our deep-learning model estimates HLS Therapeutics Inc.'s (HLS.TO) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $66.50
- Current price
- $4.64
- AI upside
- +1,333.19%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$2.71
-41.59% upside
Graham-Dodd
—
— upside
Graham Formula
$1.40
-69.83% upside
About HLS Therapeutics Inc.
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also offers MyCare psychiatry lab assays and MyCare Insite point of care therapeutic drug-level monitoring tests. In addition, the company holds the U.S. marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia for CV therapeutics; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. was founded in 2018 and is headquartered in Etobicoke, Canada.
- CEO
- Craig Stuart Millian
- Employees
- 92
- Beta
- 0.90
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($2.71 ÷ $4.64) − 1 = -41.59% (DCF, example).